Status:
COMPLETED
Eon® Flanks Safety Clinical Study Protocol
Lead Sponsor:
Dominion Aesthetic Technologies, Inc.
Conditions:
Adipose Tissue
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
This study is designed to provide objective evidence regarding the safety of eon® treatment of the flanks.
Detailed Description
This study is designed to provide objective evidence regarding the safety of eon® treatment of the flanks.
Eligibility Criteria
Inclusion
- Subject is a healthy male or female \> 18 years or older seeking treatment for unwanted fat in the flanks.
- Subject must be able to read, understand and sign the Informed Consent Form (ICF) in English.
- Subject has sufficient thickness (≥ 20 mm) of adipose tissue on the flanks area.
- Subject must be willing and able to adhere to the treatment and follow-up visit schedule.
- Subject is willing to have photographs and ultrasound measurements taken of the treated area.
- Female subjects must be using medically acceptable form of birth control during the entire course of the study or may be post-menopausal, or surgically sterilized.
Exclusion
- • Subject had an aesthetic fat reduction procedure in the treatment area within the previous year
- Subject was pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in last 6 months
- Subject has an infection, dermatitis or a rash in the treatment area.
- Subject has tattoos or jewelry in the treatment area or within the treatment area site or photography frame.
- Subject has a history of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- Subject has a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- Subject has a history of a known bleeding disorder.
- Subject has a known photosensitivity to the study laser wavelength, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light.
- Subject has known collagen, vascular disease or scleroderma.
- Subject has undergone a surgery or procedure in the treatment area within 6 months of treatment, which is still healing.
- Subject suffers from significant concurrent illness, such as insulin-dependent diabetes, peripheral vascular disease or peripheral neuropathy.
- Subject is undergoing systemic chemotherapy for the treatment of cancer.
- Subject is using gold therapy for disorders such as rheumatologic disease or lupus.
- Subject has participated in a study of another device or drug within three months prior to enrollment or during the study.
- As per the investigator's discretion, the subject has any physical or mental condition which might make it unsafe for the subject to participate in this study.
- Subject has ongoing use of steroids or secondary rheumatoid drugs.
- Subject is actively taking psychotropic medications.
Key Trial Info
Start Date :
February 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2021
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04797988
Start Date
February 6 2021
End Date
May 15 2021
Last Update
June 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fiala Aesthetics
Altamonte Springs, Florida, United States, 32701